PMID- 16519663
OWN - NLM
STAT- MEDLINE
DCOM- 20060509
LR  - 20181113
IS  - 0953-816X (Print)
IS  - 1460-9568 (Electronic)
IS  - 0953-816X (Linking)
VI  - 23
IP  - 4
DP  - 2006 Feb
TI  - Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through 
      delta- and micro-opioid receptors independent of antidepressant-like effects.
PG  - 984-94
AB  - Systemic administration of delta-opioid receptor (DOR) agonists decreases 
      immobility in the forced swim test (FST) and increases brain-derived neurotrophic 
      factor (BDNF) mRNA expression in rats, indicating that DOR agonists may have 
      antidepressant-like effects. The aim of this study was to investigate the effects 
      of central administration of endogenous opioid peptides on behavior in the FST 
      and on brain BDNF mRNA expression in rats. Effects of endogenous opioids were 
      compared with those produced by intracerebroventricular administration of a 
      selective non-peptidic DOR agonist (+)BW373U86. Antidepressant-like effects were 
      measured by decreased immobility in the FST. BDNF mRNA expression was determined 
      by in situ hybridization. Centrally administered (+)BW373U86 decreased immobility 
      and increased BDNF mRNA expression in the frontal cortex through a DOR-mediated 
      mechanism, because these effects were blocked by the DOR antagonist naltrindole, 
      but not by the micro-opioid receptor (MOR) antagonist naltrexone (NTX) or the 
      kappa-opioid receptor antagonist nor-binaltorphimine. Of all the endogenous 
      opioids tested, only leu- and met-enkephalin produced behavioral effects like 
      those of (+)BW373U86 in the FST. Unlike (+)BW373U86, the enkephalins upregulated 
      BDNF mRNA expression in the hippocampus through DOR- and MOR-mediated mechanisms. 
      beta-Endorphin, endomorphin-1 and endomorphin-2 significantly increased BDNF mRNA 
      levels in the frontal cortex, hippocampus and amygdala without reducing 
      immobility; and most of these effects were reversed by NTX. This study is the 
      first to provide evidence that endogenous opioids can upregulate BDNF mRNA 
      expression through the DOR and MOR, and that leu- and met-enkephalin have similar 
      pharmacological profiles to synthetic DOR agonists in producing 
      antidepressant-like effects.
FAU - Zhang, Huina
AU  - Zhang H
AD  - Department of Pharmacology, University of Michigan Medical School, Ann Arbor, 
      Michigan 48109, USA.
FAU - Torregrossa, Mary M
AU  - Torregrossa MM
FAU - Jutkiewicz, Emily M
AU  - Jutkiewicz EM
FAU - Shi, Yong-Gong
AU  - Shi YG
FAU - Rice, Kenner C
AU  - Rice KC
FAU - Woods, James H
AU  - Woods JH
FAU - Watson, Stanley J
AU  - Watson SJ
FAU - Ko, M C
AU  - Ko MC
LA  - eng
GR  - MH42251/MH/NIMH NIH HHS/United States
GR  - T32 DA007281/DA/NIDA NIH HHS/United States
GR  - P01 MH042251/MH/NIMH NIH HHS/United States
GR  - DA13685/DA/NIDA NIH HHS/United States
GR  - P01 DA000254/DA/NIDA NIH HHS/United States
GR  - R01 DA013685/DA/NIDA NIH HHS/United States
GR  - DA00254/DA/NIDA NIH HHS/United States
GR  - DA07281/DA/NIDA NIH HHS/United States
GR  - K21 DA000254/DA/NIDA NIH HHS/United States
GR  - P50 DA000254/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - France
TA  - Eur J Neurosci
JT  - The European journal of neuroscience
JID - 8918110
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Benzamides)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Narcotics)
RN  - 0 (Opioid Peptides)
RN  - 0 (Piperazines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Opioid, delta)
RN  - 0 (Receptors, Opioid, mu)
RN  - 150428-54-9 (BW 373U86)
RN  - 5S6W795CQM (Naltrexone)
RN  - G167Z38QA4 (naltrindole)
SB  - IM
MH  - Analgesics, Opioid/pharmacology
MH  - Analysis of Variance
MH  - Animals
MH  - Autoradiography/methods
MH  - Behavior, Animal
MH  - Benzamides/administration & dosage
MH  - Brain-Derived Neurotrophic Factor/genetics/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Freezing Reaction, Cataleptic/drug effects
MH  - In Situ Hybridization/methods
MH  - Injections, Intraventricular/methods
MH  - Male
MH  - Naltrexone/analogs & derivatives/pharmacology
MH  - Narcotics/*metabolism
MH  - Opioid Peptides/administration & dosage
MH  - Piperazines/administration & dosage
MH  - RNA, Messenger/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Opioid, delta/*physiology
MH  - Receptors, Opioid, mu/*physiology
MH  - Swimming
MH  - Up-Regulation/drug effects/physiology
PMC - PMC1462954
MID - NIHMS9647
EDAT- 2006/03/08 09:00
MHDA- 2006/05/10 09:00
PMCR- 2008/01/26
CRDT- 2006/03/08 09:00
PHST- 2006/03/08 09:00 [pubmed]
PHST- 2006/05/10 09:00 [medline]
PHST- 2006/03/08 09:00 [entrez]
PHST- 2008/01/26 00:00 [pmc-release]
AID - EJN4621 [pii]
AID - 10.1111/j.1460-9568.2006.04621.x [doi]
PST - ppublish
SO  - Eur J Neurosci. 2006 Feb;23(4):984-94. doi: 10.1111/j.1460-9568.2006.04621.x.